Ditiocarb

Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunoresearch of high risk breast cancer[1][2][3].

Product Specifications

CAS Number

[147-84-2]

Product Name Alternative

Diethyldithiocarbamic acid

UNSPSC

12352211

Hazard Statement

H302-H312-H332

Target

HIV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/ditiocarb.html

Solubility

10 mM in DMSO

Smiles

SC(N(CC)CC)=S

Molecular Formula

C5H11NS2

Molecular Weight

149.28

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41 (4) :289-293.|[2]Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265 (12) :1538-44.|[3]Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6 (1) :9-12.